Closed · RFA-FD-11-026 · CFDA 93.103 · Discretionary

Advancing Regulatory Science Through Development of Innovative Methodologies in the area of Antimicrobial Development (U01)

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$50K-$100K
Award range
Closed
Status
July 2, 2011
Close date
6
Expected awards

The verdict

Advancing Regulatory Science Through Development of Innovative Methodologies in the area of Antimicrobial Development (U01) is a closed discretionary listing from Food and Drug Administration that offered $50,000 -- $100,000 across 6 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$50K-$100K
award range
Closed
application status
6
expected awards
93.103
CFDA program

Archived opportunity record

Advancing Regulatory Science Through Developm… is closed (last close July 2, 2011). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed July 2, 2011

Posted May 23 Closes Jul 2

Est. Total Funding

$500,000

Expected Awards

6

Instrument

Cooperative Agreement

Description

PLEASE NOTE: The correct contact information for the project officer is as follows: Nancy Masiello Telephone: 301-796-8498 and FAX: 301-847-8614. FDA is announcing an FOA for research into innovative methodologies in the area of antimicrobial development that can have an impact on the selection of the appropriate dosing and/or combination regimens to prevent emergence of antimicrobial resistance.This FOA is part of the Critical Path Initiative's (CPI's) long-term strategic effort to drive innovation in medical product development. CPI forms a key component of a broader FDA initiative, Advancing Regulatory Science, which focuses on developing new tools, standards, and approaches to assess the safety, efficacy, quality and performance of all FDA-regulated products.There is growing concern over the development of antimicrobial resistance. Even newer antimicrobials such as fluoroquinolones which formerly showed excellent broad spectrum activity are losing their value as the prevalence of resistant organisms continues to increase. Strategies have been explored to curtail the development of resistance. These range from restricting the use of certain antimicrobials, to elaborate infection control measures to prevent the spread of these organisms, to programs for antimicrobial stewardship.Mounting evidence suggests that combinations of antimicrobials and/or high dose and short duration therapy are promising strategies to combat the emergence of resistance. High drug exposure is often necessary to suppress the emergence of resistance and can involve increase in dose, or dosing frequency, or changes in the method of dose administration (e.g., extending infusion time). Combination antimicrobial therapy might prevent emergence of resistance by acting on multiple bacterial targets while simultaneously reducing the effective dose of individual drugs.The use of combination antimicrobials to prevent emergence of resistance and improve patient outcomes is standard practice in the treatment of tuberculosis, H. pylori, HIV, and currently malaria.The development of new antibacterial agents typically focuses on primary efficacy and the generation of resistance has not been a major consideration. This approach carries a legacy of failure with widespread resistance to almost all available agents.The purpose of this FOA is to investigate the potential value of novel PK/PD-based dosing and combination therapy approaches in preventing the development of antimicrobial resistance.[4] New modeling systems, such as in vitro hollow fiber systems, may be helpful in clarifying the potential value of these approaches. Areas of primary concern are Gram-negative pathogens that are frequent in health care settings as well as in the community, and are commonly treated with single agents, e.g. pathogens responsible for uncomplicated urinary tract infections. Many of these organisms, including E. coli, K. pneumoniae, Serratia, Acinetobacter, Proteus, P. aeruginosa, and Enterobacter spp., exhibit growing resistance to multiple antimicrobial agents.

Campus–civic applicant bridge · 4 doors

Advancing Regulatory Science Through Developm… bridges educational institutions with civic applicant types (4 doors: Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Private institutions of higher education; Others (see official listing text)). Expect campus and public/nonprofit operators in the same printed set. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). Inside Food and Drug Administration's indexed book this exact eligibility-code string is unique to this listing.

Code 06
Public / state-controlled institutions of higher education
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez Grants Management Specialist Phone 301-827-7168

What to do next

Advancing Regulatory Science Through Developm… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants